• 1
    Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914921.
  • 2
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:32553264.
  • 3
    Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Lancet. 1997;350:757764.
  • 4
    Heart Disease and Stroke. Accessed April 19, 2007.
  • 5
    Rosamond W, Flegal K, Furie K, et al., for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics 2008 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25e146.
  • 6
    Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155:829837.
  • 7
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199206.
  • 8
    Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 9
    Centers for Disease Control and Prevention (CDC). Racial/ethnic disparities in prevalence, treatment, and control of hypertension--United States, 1999–2002. Morb Mortal Wkly Rep. 2005;54:79.
  • 10
    Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49:6975.
  • 11
    Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2002;4:393404.
  • 12
    Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:19571963.
  • 13
    Cramer JA. Consequences of intermittent treatment for hypertension: The case for medication compliance and persistence. Am J Manag Care. 1998;4:15631568.
  • 14
    Gupta K, Gupta S. Undertreatment of hypertension: A dozen reasons. Arch Intern Med. 2002;162:22462247.
  • 15
    Chalmers J. Impact of guidelines for antihypertensive treatment on clinical practice. Clin Exp Hypertens. 1996;18:415423.
  • 16
    Stillman FA. Focus group research: an overview. In: BeckerDM, HillDR, LacksonJS, LevineDM, StillmanFA, WeissSM, eds. Health Behavior Research in Minority Populations: Access, Design, and Implementation, 1st ed. Bethesda, MD: U.S. Department of Health and Human Services; 1992:168175.
  • 17
    Gallagher TH, Waterman AD, Ebers AG, Fraser VJ, Levinson W. Patients’ and physicians’ attitudes regarding the disclosure of medical errors. JAMA. 2003;289:10011007.
  • 18
    Giacomini MK, Cook DJ, for the Evidence-Based Medicine Working Group. Users’ guides to the medical literature: XXIII. Qualitative research in health care A. Are the results of the study valid? JAMA. 2000;284:357362.
  • 19
    Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens. 1996;9: 342360.
  • 20
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 21
    Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239246.
  • 22
    Morgan DL. Focus Groups as Qualitative Research, 2nd ed. Thousand Oaks, CA: Sage Publications, Inc.; 1997.
  • 23
    Seidel J, Friese S, Leonard DC. The Ethnograph, 4th ed. Amherst, MA: Qualis Research Associates; 1995.
  • 24
    Crabtree BF, Miller WL. A template approach to text analysis: Developing and using codebooks. In: CrabtreeBF, MillerWL, eds. Doing Qualitative Research, 1st ed. Newbury Park, CA: Sage Publications; 1992:93109.
  • 25
    Stewart M, Brown JB, Donner A, et al. The impact of patient-centered care on outcomes. J Fam Pract. 2000; 49:796804.
  • 26
    Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (SYST-CHINA) Collaborative Group. J Hypertens. 1998;16:18231829.
  • 27
    Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:310.
  • 28
    Lincoln Y, Guba E. Naturalistic Inquiry. Beverly Hills, CA: Sage Publications, Inc.; 1985.